:: Volume 24, Issue 2 (4-2026) ::
Int J Radiat Res 2026, 24(2): 487-493 Back to browse issues page
Reduction of cat allergen levels based on anti-Fel d1 andanti-Fel d4 IgY after radiotherapy
W. Chai , S. Han , M. Deng , J. Ma , Y. Li , Q. Shi , W. Zhang , Y. Xu , M. Dong , Z. Dai
School of Pharmacy, Qingdao University, Haoyuan Medical Education Comprehensive Building, Fushan Campus, Qingdao City, China , Mxdong64@qdu.edu.cn
Abstract:   (593 Views)
Background: Fel d 1 and Fel d 4 are the major feline allergens responsible for allergic responses in sensitized individuals. Immunoglobulin Y (IgY) antibodies can neutralize allergens, while low-dose radiotherapy may transiently alter glandular secretion. To evaluate the combined effect of anti-Fel d 1 and anti-Fel d 4 IgY and controlled low-dose radiotherapy on reducing allergen levels in cats. Materials and Methods: Cats received localized low-dose radiotherapy (2 Gy delivered in two fractions) followed by oral supplementation with purified and lyophilized anti-Fel d 1 and anti-Fel d 4 IgY. Allergen concentrations in saliva and hair were measured weekly over six weeks using ELISA. IgY purity, titer stability, and neutralizing activity were assessed in-vitro. Results: IgY purity ranged from 80–90% and titers remained stable after lyophilization. Radiotherapy alone produced a transient 10–15% reduction in salivary allergen secretion. With IgY administration, salivary Fel d 1 decreased from 4.50 μg/mL to 0.28 μg/mL (−94%) and hair Fel d 1 from 1.30 μg/mL to 0.15 μg/mL (−88%) by week six. Salivary Fel d 4 decreased from 12.0 μg/mL to 1.70 μg/mL (−86%). No radiation-related adverse effects were observed. Conclusion: Low-dose radiotherapy produced a short-term decrease in allergen secretion, while IgY supplementation resulted in a sustained and substantial reduction of Fel d 1 and Fel d 4 levels. This combined approach may represent a practical strategy for reducing environmental cat allergen exposure.
Keywords: Fel d 1, Fel d 4, immunoglobulins, radiotherapy, cat allergens, hypersensitivity, enzyme-linked immunosorbent assay.
Full-Text [PDF 956 kb]   (195 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. Satyaraj E, Sun P, Sherrill S (2021) Fel d1 blocking antibodies: a novel method to reduce IgE-mediated allergy to cats. J Immunol Res, 2021: 5545173-9. [DOI:10.1155/2021/5545173]
2. Shamji MH, Singh I, Layhadi JA (2021) Passive prophylactic administration with a single dose of anti-Fel d1 monoclonal antibodies REGN1908-1909 in cat allergen-induced allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med, 204: 23-33. [DOI:10.1164/rccm.202011-4107OC]
3. Hendrickson OD, Zvereva EA, Zherdev AV, et al. (2022) Double qualitative immunochromatographic test for simultaneous control of chicken muscles and eggs in food. J Food Compos Anal, 106: 104324-30. [DOI:10.1016/j.jfca.2021.104324]
4. Xie W, Zhao W, Zou Z, et al. (2021) Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL/6 mice. Helicobacter, 26: e12807-e18. [DOI:10.1111/hel.12807]
5. Brackett NF, Pomés A, Chapman MD (2021) The major cat allergen, Fel d1, is a viable target for CRISPR gene editing. J Allergy Clin Immunol, 147: 175-83. [DOI:10.1016/j.jaci.2020.12.617]
6. Leonard C, Montamat G, Davril C, et al. (2021) Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d1-specific immunotherapy using high-dose CpG adjuvant. Allergy, 76: 2153-65. [DOI:10.1111/all.14716]
7. Almawash S, Quadir SS, Saqr AA, et al. (2022) Dual delivery of fluticasone propionate and levocetirizine dihydrochloride for the management of atopic dermatitis using a microemulsion-based topical gel. ACS Omega, 7: 7696-705. [DOI:10.1021/acsomega.1c06393]
8. Matsuura R, Kawamura A, Ota R, et al. (2023) TiO2-photocatalyst-induced degradation of dog and cat allergens under wet and dry conditions causes a loss in their allergenicity. Toxics, 11: 718-33. [DOI:10.3390/toxics11080718]
9. Wang L, Lynch C, Pitroda SP, Piffkó A, Yang K, Huser AK, et al. (2024) Radiotherapy and immunology. Journal of Experimental Medicine, 221(7): e20232101. [DOI:10.1084/jem.20232101]
10. Shukla SK, Sharma AK, Bajaj S, Yashavarddhan MH (2021) Radiation proteome: a clue to protection, carcinogenesis, and drug development. Drug Discovery Today, 26(2): 525-31. [DOI:10.1016/j.drudis.2020.10.024]
11. Guilbaud E, Naulin F, Meziani L, Deutsch E, Galluzzi L (2025) Impact of radiation therapy on the immunological tumor microenvironment. Cell Chemical Biology, 32(5): 678-93. [DOI:10.1016/j.chembiol.2025.04.001]
12. Calzetta L, Aiello M, Frizzelli A, et al. (2022) Investigational treatments in phase I and II clinical trials: a systematic review in asthma. Biomedicines, 10(9): 2330-53. [DOI:10.3390/biomedicines10092330]
13. Ureti J and Bufan B (2021) Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. Arh Farm, 71: 101-19. [DOI:10.5937/arhfarm71-30505]
14. Yu Z, Su H, Chen J, et al. (2022) Deciphering conformational changes of the GDP-bound NRAS induced by mutations G13D, Q61R, and C118S through Gaussian accelerated molecular dynamic simulations. Molecules, 27: 5596-615. [DOI:10.3390/molecules27175596]
15. Wang C, Du J, Mei X, et al. (2021) The value of effective lung ventilation area ratio based on CT image analysis as a new index to predict the shorter outcome of anti-melanoma differentiation-associated protein 5 positive dermatomyositis associated interstitial lung disease: a single-center retrospective study. Front Med, 8: 728487-502. [DOI:10.3389/fmed.2021.728487]
16. Nadeau KC (2021) Allergen-specific IgG antibodies for cat allergy? Am J Respir Crit Care Med, 204: 1-2.
17. Mehboob S, Mehboob M, Saleem DM, et al. (2021) Spectroscopic interaction studies of H2 receptor antagonists with levocetirizine. Pak J Pharm Sci, 46: 1265-9.
18. Nikolov G, Todordova Y, Emilova R, et al. (2021) Allergen-specific IgE and IgG4 as biomarkers for immunologic changes during subcutaneous allergen immunotherapy. Antibodies (Basel), 10: 49-57. [DOI:10.3390/antib10040049]
19. Platts-Mills TAE, Keshavarz B, Wilson JM, et al. (2021) An overview of the relevance of IgG4 antibodies in allergic disease with a focus on food allergens. Children (Basel), 8: 418-31. [DOI:10.3390/children8050418]
20. Wedner JH, Mantia T, Satyaraj E, et al. (2021) Feeding cats egg product with polyclonal anti-Fel d1 antibodies decreases environmental Fel d1 and allergic response: a proof-of-concept study. J Allergy Infect Dis, 2: 1-8. [DOI:10.46439/allergy.2.015]
21. Charles F, Schuler M, Montejo J, et al. (2019) Allergic rhinitis in children and adolescents. Pediatr Clin North Am, 66: 981-93. [DOI:10.1016/j.pcl.2019.06.004]
22. Kamal MA, Dingman R, Wang CQ, et al. (2021) REGN1908-1909 monoclonal antibodies block Fel d1 in cat allergic subjects: translational pharmacokinetics and pharmacodynamics. Clin Transl Sci, 14: 2440-9. [DOI:10.1111/cts.13112]
23. Shamji MH, Valenta R, Jardetzky T, et al. (2021) The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy, 76: 3627-41. [DOI:10.1111/all.14908]
24. Steinberg JA (2021) The curious history behind a biologic-enriched cat food: hyperimmune avian IgY as a means of oral adoptive passive immunization. J Allergy Clin Immunol, 148: 1473-5. [DOI:10.1016/j.jaci.2021.06.031]
25. de Blay FJ, Gherasim A, Domis N, et al. (2022) REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit. J Allergy Clin Immunol, 150: 1437-46. [DOI:10.1016/j.jaci.2022.06.025]
26. Bergmann KC, Raab J, Graessel A, et al. (2023) The holo β-lactoglobulin lozenge reduces symptoms in cat allergy: evaluation in an allergen exposure chamber and by titrated nasal allergen challenge. Clin Transl Allergy, 13: e12274-e83. [DOI:10.1002/clt2.12274]
27. Lynch C, Pitroda SP, Weichselbaum RR (2024) Radiotherapy, immunity, and immune checkpoint inhibitors. The Lancet Oncology, 25(8): e352-e62. [DOI:10.1016/S1470-2045(24)00075-5]
28. Shukla PK, Rao RG, Meena AS, Giorgianni F, Lee SC, Raju P, et al. (2023) Paneth cell dysfunction in radiation injury and radio-mitigation by human α-defensin 5. Frontiers in Immunology, 14: 2023. [DOI:10.3389/fimmu.2023.1174140]
29. Jasmer KJ, Gilman KE, Muñoz Forti K, Weisman GA, Limesand KH (2020) Radiation-induced salivary gland dysfunction: mechanisms, therapeutics and future directions. Journal of Clinical Medicine, 9(12): 4095. [DOI:10.3390/jcm9124095]
30. Ogita M, Sekiguchi K, Akahane K, Ito R, Haga C, Arai S, et al. (2015) Damage to Sebaceous Glands Within a Radiation Field and the Surrounding Tissue After Whole-Breast Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys, 93(3): E10. [DOI:10.1016/j.ijrobp.2015.07.568]
31. Blitzer GC, Paz C, McCoy SS, Kimple RJ (2025) Radiation-therapy related salivary dysfunction. Seminars in Radiation Oncology, 35(2): 278-84. [DOI:10.1016/j.semradonc.2025.02.006]

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 24, Issue 2 (4-2026) Back to browse issues page